The monitoring of antibiotic use and bacterial resistance to antibiotics in healthcare facilities, a task entrusted to the Spares initiative since 2018, contributes to the national policy on controlling antibiotic resistance by promoting the appropriate use of antibiotics and preventing cross-transmission. Its objectives are to enable each HC to describe and analyze its consumption and bacterial resistance at the department level, in comparison with a comparable group of HCs, as well as to produce indicators at the regional and national levels. The consumption of systemic ATBs in class J01 of the Anatomical Therapeutic Chemical (ATC) classification, rifampicin, oral imidazoles, and fidaxomicin, dispensed during inpatient stays, were expressed in defined daily doses (DDD) and reported relative to activity according to national and World Health Organization recommendations (ATC-DDD system, 2022). Resistance rates were expressed by taking into account "resistant" and "intermediate" strains. The 1,573 healthcare facilities participating in the antibiotic consumption surveillance program accounted for 78% of hospital days in France in 2022 and had consumed 296 DDD/1,000 hospital days (DH). The most commonly used antibiotics were the amoxicillin-clavulanic acid combination (23%), amoxicillin (13%), and ceftriaxone (6%). Antibiotic consumption ranged from 38 DDD/1,000 HD in psychiatric hospitals to 542 in cancer treatment centers. Variations were observed across specialties, ranging from 40 DDD/1,000 HD in psychiatry to 1,293 in infectious diseases. Across all healthcare facilities that participated at least once between 2012 and 2022, overall antibiotic consumption decreased (-4.1%), but it increased between 2019 and 2022 (+3.9%). The use of fluoroquinolones, in particular, has steadily declined. The use of glycopeptides has decreased since 2015, in favor of new antibiotics targeting methicillin-resistant Staphylococcus aureus (MRSA). Over the period, the use of broad-spectrum β-lactams (carbapenems, third- and fourth-generation cephalosporins, piperacillin-tazobactam combination) increased. The 942 healthcare facilities participating in the surveillance of bacterial antibiotic resistance accounted for 51% of hospital bed-days in France in 2022, according to the Annual Statistics of Healthcare Facilities (SAE). Among Enterobacteriaceae, 7.5% produced extended-spectrum beta-lactamases (ESBLs), with significant variations depending on the clinical specialty (ranging from 3.7% in gynecology and obstetrics to 15.4% in long-term care). The majority (63%) of the 27,693 ESBL-producing strains were isolated from urine specimens. Among Staphylococcus aureus strains, the percentage of methicillin resistance was 12.0%. More than 40% of the 7,454 MRSA strains were isolated from patients hospitalized in medical wards. Data on emerging highly resistant bacterial infections were collected. Carbapenemase-producing Enterobacteriaceae (CPE) were most commonly found in urine specimens (44.4%), and the most prevalent species was Klebsiella pneumoniae (33.2% of the 1,297 CPE strains). Vancomycin-resistant Enterococcus faecium strains were also most frequently isolated from urine samples (56.3% of the 96 strains). Network-based surveillance enables each healthcare facility to analyze its own situation, compare itself with others, and identify trends and areas for improvement. Controlling antibiotic resistance requires knowledge and analysis of antibiotic consumption and bacterial resistance data. These data must be supplemented by monitoring indicators of prescription appropriateness as well as by evaluating practices for preventing cross-transmission.